2. Search Result
Search Result
Pathways Recommended: Membrane Transporter/Ion Channel
Results for "

lung membranes

" in MedChemExpress (MCE) Product Catalog:

87

Inhibitors & Agonists

4

Fluorescent Dyes

4

Biochemical Assay Reagents

6

Peptides

2

Inhibitory Antibodies

15

Natural
Products

1

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19989
    MK-571
    Maximum Cited Publications
    33 Publications Verification

    L-660711

    		 P-glycoprotein LPL Receptor Leukotriene Receptor Inflammation/Immunology
    MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .
    MK-571
  • HY-109061
    Lazertinib
    3 Publications Verification

    YH25448; GNS-1480

    		 Apoptosis Akt TRP Channel EGFR ERK Infection Neurological Disease Metabolic Disease Cancer
    Lazertinib (YH25448; GNS-1480) is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
    Lazertinib
  • HY-19989A
    MK-571 sodium
    Maximum Cited Publications
    33 Publications Verification

    L-660711 sodium

    		 P-glycoprotein LPL Receptor Leukotriene Receptor Inflammation/Immunology
    MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .
    MK-571 sodium
  • HY-D1063
    IR-780
    5+ Cited Publications

    		 Fluorescent Dye Apoptosis Reactive Oxygen Species (ROS) Cancer
    IR-780 is a near-infrared fluorescent probe for in vivo imaging of tumor cells. IR-780 is transported into tumor cells via OATPs and ABCB10, with uptake dependent on glycolytic activity and plasma membrane potential. IR-780 preferentially accumulates in tumor cell mitochondria, including those of drug-resistant cancer cells, without chemical conjugation. IR-780 generates reactive oxygen species (ROS), induces hyperthermia and apoptosis, inhibits tumor growth and recurrence, and modulates HSP70 expression upon ultrasound or 808 nm laser exposure. IR-780 acts as a sonosensitizer, photodynamic and photothermal agent, and drug delivery carrier, with low acute imaging-dose toxicity and rapid vital organ clearance. IR-780 can be used for the research of cancer, such as breast cancer, lung cancer, and non-small cell lung cancer (NSCLC) .
    IR-780
  • HY-N1462
    Atractyloside potassium salt
    4 Publications Verification

    		 Chloride Channel Autophagy mTOR AMPK Cardiovascular Disease Metabolic Disease Cancer
    Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity .
    Atractyloside potassium salt
  • HY-P5423
    GALA

    		Exosomes Liposome Cancer
    GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. GALA significantly promotes the cytosolic release of cargos carried by exosomes, plasmids and liposomes, effectively enhances gene transfection efficiency, and drives gene knockdown of functional macromolecules (such as siRNA) in alveolar epithelial cells (with no significant cytotoxicity at effective concentrations). GALA serves as a critical tool for studies on lung cancer metastasis (e.g., melanoma lung metastasis) and lung-targeted drug delivery systems .
    GALA
  • HY-B0290
    Pranlukast
    3 Publications Verification

    ONO-1078

    		 Leukotriene Receptor Endogenous Metabolite Inflammation/Immunology
    Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ 3H]LTE4, [ 3H]LTD4, and [ 3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
    Pranlukast
  • HY-156617A
    (αR)-Cyclopropaneacetamide-Exatecan

    SHR169265

    		 ADC Payload Topoisomerase Cancer
    (αR)-Cyclopropaneacetamide-Exatecan (SHR169265) is a DNA Topoisomerase I inhibitor with enhanced membrane permeability (with an IC50 of 1.34 μM against the human DNA Topoisomerase I). (αR)-Cyclopropaneacetamide-Exatecan exerts cytotoxic effects by inhibiting the enzymatic activity of Topoisomerase I, and this anticancer effect is independent of the expression level of HER2. (αR)-Cyclopropaneacetamide-Exatecan is an ADC Cytotoxin derived from Exatecan (HY-13631), which can be used in research related to advanced cancers such as breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer .
    (αR)-Cyclopropaneacetamide-Exatecan
  • HY-124108
    Eicosatetraynoic acid

    ETYA

    		 COX Lipoxygenase Orthopoxvirus Potassium Channel DNA/RNA Synthesis Drug Derivative Infection Neurological Disease Inflammation/Immunology Cancer
    Eicosatetraynoic acid (ETYA) is a non-metabolizable analog of Arachidonic acid (HY-109590) and also an inhibitor of the lipoxygenase (LOX)/cyclooxygenase (COX) pathway (ID50 = 8 μM and 4 μM). Eicosatetraynoic acid acts as a suicide substrate to inhibit the production of inflammatory mediators such as leukotrienes and prostaglandins. Eicosatetraynoic acid acts directly on cell membranes and membrane proteins to exert a wide range of effects, including blocking potassium channels, increasing cell membrane fluidity, elevating intracellular calcium levels, inhibiting DNA synthesis in tumor cells, inducing differentiation of certain cells, and specifically inhibiting the assembly and replication of orthopoxviruses. Eicosatetraynoic acid alleviates acute lung injury induced by chemicals such as phosgene .
    Eicosatetraynoic acid
  • HY-B1513
    α-Cyclodextrin
    2 Publications Verification

    		 Environmental Pollutants SARS-CoV Microtubule/Tubulin Infection Metabolic Disease Cancer
    α-Cyclodextrin (α-CD) is a soluble fiber derived from corn. α-Cyclodextrin can deplete sphingolipids and phospholipids from cell membranes. α-Cyclodextrin interacts with tubulin. α-Cyclodextrin improves defenses against SARS-CoV-2 infection. α-Cyclodextrin enhances the anticancer efficacy of Crcumin (HY-N0005) against breast, lung and cervical cancer. α-Cyclodextrin has beneficial effects on body weight and blood lipids .
    α-Cyclodextrin
  • HY-N3980
    Guaiol
    1 Publications Verification

    Champacol; Guaiac alcohol

    		 Autophagy RAD51 Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Guaiol is a sesquiterpenoid alcohol with oral activity found in various traditional Chinese medicines, exhibiting biological activities such as anti-proliferative, autophagy-promoting, insecticidal, anti-anxiety, anti-inflammatory, diuretic, and blood pressure-lowering effects. Guaiol induces apoptosis in non-small cell lung cancer cells by regulating the stability of RAD51 through autophagy modulation. Guaiol can also act directly on parasites, inhibiting their growth by affecting the kinetoplast, mitochondrial matrix and plasma membrane of the promastigotes. Guaiol kills amastigotes at an IC50 of 0.01 µg/mL. Guaiol can be used in research related to cancer, infections, cardiovascular diseases, and inflammatory conditions [4]
    Guaiol
  • HY-P1408
    Obtustatin
    4 Publications Verification

    		 Integrin VEGFR Cancer
    Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .
    Obtustatin
  • HY-N1431
    Tabersonine
    3 Publications Verification

    		 NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK Inflammation/Immunology Cancer
    Tabersonine is a selective, orally active NLRP3 inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .
    Tabersonine
  • HY-109061B
    Lazertinib mesylate
    3 Publications Verification

    YH25448 mesylate; GNS-1480 mesylate

    		 TRP Channel EGFR Akt ERK Apoptosis Cancer
    Lazertinib (YH25448; GNS-1480) mesylate is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib mesylate exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib mesylate induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib mesylate competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib mesylate is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
    Lazertinib mesylate
  • HY-15744
    LY255283
    3 Publications Verification

    		 Leukotriene Receptor Inflammation/Immunology Cancer
    LY255283 is a LTB4 receptor (BLT2) antagonist, with an IC50 of ~100 nM for [ 3H]LTB4 binding to guinea pig lung membranes .
    LY255283
  • HY-P991669
    IGN523

    AML-01

    		 Caspase Apoptosis Cancer
    IGN523 is an anti-CD98 antibody (hCD98, KD = 0.55 nM). IGN523 induces antibody-dependent cell-mediated cytotoxicity (ADCC) activity, lysosomal membrane permeabilization, and inhibition of essential amino acid transport, ultimately leading to caspase-3 and caspase-7-mediated apoptosis of tumor cells. IGN523 inhibits tumor growth in multiple tumor xenograft models. IGN523 is useful in the research of non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and other cancers. .
    IGN523
  • HY-172760
    CIM-834

    		SARS-CoV Infection
    CIM-834 is an orally effective inhibitor of SARS-CoV-2 membrane protein. CIM-834 can prevent the assembly of infectious virus particles without inhibiting the synthesis of viral RNA. CIM-834 can reduce the viral titer in the lungs of SCID mice infected nasally with SARS-CoV-2, block the spread of SARS-CoV-2 among Syrian hamsters, and inhibit the replication of SARS-CoV-2 (including variants) and SARS-CoV. CIM-834 can be used in related research on COVID-19 .
    CIM-834
  • HY-B0984
    Fendiline hydrochloride
    3 Publications Verification

    		 Calcium Channel Ras STING Autophagy Infection Cardiovascular Disease Cancer
    Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline hydrochloride
  • HY-59137
    1-Methylimidazole

    		Drug Intermediate Cancer
    1-Methylimidazole acts as a membrane performance regulator that promotes the formation of reverse osmosis membranes with a dense ultra-thin polyamide layer. Such membranes exhibit higher flux and salt rejection rate, while also conferring excellent pH stability to the membrane. 1-Methylimidazole can serve as a ligand for ruthenium (II) complexes to construct metal-based anticancer agents .
    1-Methylimidazole
  • HY-N5112A
    β,β-Dimethylacrylalkannin
    3 Publications Verification

    Arnebin 1

    		 FGFR Necroptosis Apoptosis CDK JNK Inflammation/Immunology
    β,β-Dimethylacrylalkannin (Arnebin 1) is an orally active FGFR1 inhibitor (IC50=2.5 μM) and the main active component of Lithospermum erythrorhizon. β,β-Dimethylacrylalkannin blocks downstream signaling by binding to the ATP pocket of FGFR1, and regulates the CDK1/Cdc25C pathway and ROS-JNK axis, thereby inducing G2/M phase arrest, necrosis and apoptosis in cancer cells, and inhibiting tumor proliferation. β,β-Dimethylacrylalkannin also acts as a colistin adjuvant to disrupt the cell membrane of Gram-negative bacteria. β,β-Dimethylacrylalkannin exhibits significant tumor-inhibitory effects with no obvious toxicity in PDX models, but chronic exposure to high doses may alter the relative lung/liver weights of rats, while acute exposure to high doses causes responses such as reduced motor activity. β,β-Dimethylacrylalkannin finds wide application in studies related to hepatocellular carcinoma, colorectal cancer, colistin-resistant bacterial infections, hepatitis and psoriasis .
    β,β-Dimethylacrylalkannin
  • HY-16694
    BAMB-4
    1 Publications Verification

    ITPKA-IN-C14

    		 Phosphatase Cancer
    BAMB-4 (ITPKA-IN-C14) is a specific and membrane-permeable ITPKA inhibitor. BAMB-4 has high stability and membrane permeability and against the inositol-1,4,5-trisphosphate (InsP3) kinase activity of inositol-1,4,5-trisphosphate-3-kinase A (ITPKA) with an IC50 value of 20 μM. BAMB-4 can be used for the research of metastasis of lung cancer .
    BAMB-4
  • HY-B0984A
    Fendiline
    3 Publications Verification

    		 Calcium Channel Ras STING Autophagy Infection Cardiovascular Disease Cancer
    Fendiline, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline
  • HY-P10943
    APO-15

    		Fluorescent Dye Inflammation/Immunology Cancer
    APO-15 is a phosphatidylserine-binding fluorescent probe and apoptosis imaging reagent. APO-15 exhibits high chemical stability under proteolytic and oxidative conditions, enables quantification and imaging of drug-induced apoptosis in preclinical mouse models, and is applicable to fixed tissue samples and multiple in vivo administration routes (Ex = 488 nm; Em = 525 nm). APO-15 can be used in studies related to acute lung injury and breast cancer .
    APO-15
  • HY-B0460
    Tiotropium bromide monohydrate
    2 Publications Verification

    BA-679 BR monohydrate

    		 mAChR Inflammation/Immunology
    Tiotropium bromide monohydrate (BA-679 BR monohydrate) is a long-acting anticholinergic bronchodilator. Tiotropium bromide monohydrate blocks the action of acetylcholine at muscarinic M1, M2, and M3 receptors, prevents bronchoconstriction, and dilates bronchial airways. Tiotropium bromide monohydrate is applicable to research related to chronic obstructive pulmonary disease and asthma .
    Tiotropium bromide monohydrate
  • HY-103316A
    Ned 19
    3 Publications Verification

    		 Calcium Channel Cardiovascular Disease Cancer
    Ned 19 is a selective membrane-permeant non competitive NAADP antagonist and inhibits NAADP-mediated Ca 2+ signaling, with an IC50 of 65 nM . Ned 19 strongly inhibits tumor growth and vascularization as well as lung metastases in mice .
    Ned 19
  • HY-B0290A
    Pranlukast hemihydrate
    3 Publications Verification

    ONO-1078 hemihydrate

    		 Leukotriene Receptor Endogenous Metabolite Inflammation/Immunology
    Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ 3H]LTE4, [ 3H]LTD4, and [ 3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
    Pranlukast hemihydrate
  • HY-114457
    Phosphatidylinositol 4,5-bisphosphate

    L-alpha-Phosphatidylinositol-4,5-bisphosphate; (PtdIns)-(4,5)-P2

    		 Phospholipase Inflammation/Immunology
    Phosphatidylinositol 4,5-bisphosphate (L-alpha-Phosphatidylinositol-4,5-bisphosphate) is a plasma membrane lipid that is enriched in the cytoplasmic leaflet of the plasma membrane. Phosphatidylinositol 4,5-bisphosphate serves as a substrate for phospholipase C and class I PI3K, generating diacylglycerol, inositol (1,4,5)-trisphosphate, and phosphatidylinositol (3,4,5)-trisphosphate. Phosphatidylinositol 4,5-bisphosphate contributes to lamellipodial protrusion, directional cell migration, focal adhesion lipid generation, and trafficking of the GABAA receptor. Phosphatidylinositol 4,5-bisphosphate can be used in research related to acute lung injury and pulmonary edema .
    Phosphatidylinositol 4,5-bisphosphate
  • HY-W012985
    Methyl pyruvate

    		ATP Synthase Apoptosis Metabolic Disease Cancer
    Methyl pyruvate is a methyl ester derivative of pyruvic acid. Methyl pyruvate induces insulin release and membrane depolarization. Methyl pyruvate rescues proteasome damage and nuclear localization of TdP-43 caused by overexpression of σ1RE102Q by enhancing ATP synthesis. Methyl pyruvate selectively protects normal lung fibroblasts from cell death induced by Irinotecan (HY-16562). Methyl pyruvate promotes apoptosis and necrosis in cancer cells and downregulates angiogenesis and cell cycle pathways. Methyl pyruvate is an effective substrate for dihydrodihydrogen dehydrogenase.
    Methyl pyruvate
  • HY-16942
    Damulin B
    1 Publications Verification

    		 Apoptosis Reactive Oxygen Species (ROS) Bcl-2 Family CDK MMP Interleukin Related MDM-2/p53 Metabolic Disease Inflammation/Immunology Cancer
    Damulin B is a dammarane-type saponin found in Gynostemma pentaphyllum. Damulin B can inhibit cancer cell apoptosis, decrease mitochondrial membrane potential, inhibit ROS production and cause G0/G1 phase arrest. Damulin B can prevent Cisplatin (HY-17394)-induced acute kidney injury and induce hair growth. Damulin B shows anti-inflammation anti-diabetic and anti-obesity effect. Damulin B can be used for the researches of cancer, inflammation, metabolic disease, such as lung cancer, osteoarthritis and diabetes .
    Damulin B
  • HY-D1556
    18:1 PE CF

    1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein) ammonium

    		 Fluorescent Dye Cancer
    18:1 PE CF (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein) (ammonium)) is a pH-sensitive fluorescent indicator. 18:1 PE CF exhibits changes in fluorescence intensity in response to pH variations and reflects the electrostatic states of cationic liposomes and lipoplexes. 18:1 PE CF supports real-time visualization of pH distribution and membrane deformation in giant unilamellar vesicles and is suitable for steady-state fluorescence testing in large unilamellar vesicle membranes. 18:1 PE CF is capable of monitoring the surface electrical potential of cationic liposomes and lipoplexes and can effectively label lipid bilayers and nanomicelles. 18:1 PE CF can be used for the research of the investigation of lung cancer (Ex = 495 nm; Em = 520 nm) .
    18:1 PE CF
  • HY-B0290R
    Pranlukast (Standard)

    ONO-1078 (Standard)

    		 Reference Standards Leukotriene Receptor Endogenous Metabolite Inflammation/Immunology
    Pranlukast (Standard) is the analytical standard of Pranlukast. This product is intended for research and analytical applications. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ 3H]LTE4, [ 3H]LTD4, and [ 3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
    Pranlukast (Standard)
  • HY-B0984R
    Fendiline hydrochloride (Standard)

    		Calcium Channel Ras STING Autophagy Reference Standards Infection Cardiovascular Disease Cancer
    Fendiline (hydrochloride) (Standard) is the analytical standard of Fendiline (hydrochloride). This product is intended for research and analytical applications. Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline hydrochloride (Standard)
  • HY-148365
    NecroIr1

    		Mixed Lineage Kinase RIP kinase CDK Cancer
    NecroIr1 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr1 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr1 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and Mixed Lineage Kinase (MLKL), and regulates CDK4 expression .
    NecroIr1
  • HY-148366
    NecroIr2

    		Mixed Lineage Kinase RIP kinase CDK Cancer
    NecroIr2 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr2 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr2 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), and regulates CDK4 expression .
    NecroIr2
  • HY-N1431A
    Tabersonine hydrochloride
    3 Publications Verification

    		 NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK Neurological Disease Inflammation/Immunology
    Tabersonine hydrochloride is a selective, orally active NLRP3 inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .
    Tabersonine hydrochloride
  • HY-163880
    EGFR-IN-119

    		EGFR Ras p38 MAPK Reactive Oxygen Species (ROS) Cancer
    EGFR-IN-119 (Compound 5l) is an inhibitor for EGFR with an IC50 of 84.3 nM. EGFR-IN-119 inhibits the cytotoxicity in lung cancer cell A549 with an IC50 of 1.34 μM. EGFR-IN-119 downregulates the expressions of EGFR, KRAS, and MAP2K genes, exhibits antioxidant activity through reduction of reactive oxygen species (ROS), and hyperpolarizes the mitochondrial membrane potential .
    EGFR-IN-119
  • HY-B0290AR
    Pranlukast hemihydrate (Standard)

    ONO-1078 hemihydrate (Standard)

    		 Leukotriene Receptor Endogenous Metabolite Reference Standards Inflammation/Immunology
    Pranlukast (hemihydrate) (Standard) is the analytical standard of Pranlukast (hemihydrate). This product is intended for research and analytical applications. Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
    Pranlukast hemihydrate (Standard)
  • HY-173526
    H052

    		Bacterial Calcium Channel Infection
    H052 is a selective Staphylococcus aureus α-hemolysin (Hla) inhibitor. H052 binds to Hla monomers, disrupts the interaction with host cell membranes to block pore formation, inhibiting calcium ion influx, cytotoxicity, and inflammatory responses. H052 exhibits potency (EC50=30 nM in U937 cells) against Hla-induced calcium influx. H052 is promising for research of lung infections caused by S. aureus .
    H052
  • HY-106899
    MK 287

    		Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
    MK 287
  • HY-175757
    HsClpP activator-2

    		ClpP Apoptosis Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    HsClpP activator-2 is an orally active HsClpP agonist with a KD of 40 nM. HsClpP activator-2 potently inhibits SCLC cells including H69 (IC50 = 0.17 μM) and H82 (IC50 = 0.19 μM). HsClpP activator-2 disrupts mitochondrial membrane potential (MMP), as well as induces apoptosis and ROS in H82 cells. HsClpP activator-2 significantly inhibits tumor growth in non-SMC xenograft models with a tumor growth inhibition. HsClpP activator-2 can be used for the study of small cell lung carcinoma (SCLC) .
    HsClpP activator-2
  • HY-175833
    NF-κB-IN-20

    		NF-κB Keap1-Nrf2 Heme Oxygenase (HO) Interleukin Related TNF Receptor Reactive Oxygen Species (ROS) SOD Inflammation/Immunology
    NF-κB-IN-20 is an orally active NF-κB inhibitor. NF-κB-IN-20 directly binds to the Keap1 protein, activating the Keap1/Nrf2/HO-1 antioxidant pathway, and simultaneously inhibiting the NF-κB inflammatory pathway, thereby synergistically reducing oxidative stress and inflammatory responses. NF-κB-IN-20 M11 inhibits the expression of IL-6, IL-1β, and TNF-α, significantly reduces the level of ROS, and restores the mitochondrial membrane potential. NF-κB-IN-20 can be used for the study of acute lung injury (ALI) .
    NF-κB-IN-20
  • HY-124887
    L 651142

    		Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    L 651142 is a weak platelet activating factor (PAF) receptor antagonist. L 651142 inhibits the binding of [ 3H]PAF to rabbit platelet, human platelet or human lung membranes with Kis of 0.839 μM, 1.82 μM, 3.64 μM, respectively .
    L 651142
  • HY-106899A
    (rel)-MK 287

    (rel)-L-680573

    		 Platelet-activating Factor Receptor (PAFR) Others
    (rel)-MK 287 ((rel)-L-680573) is a relative configuration of MK 287. MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
    (rel)-MK 287
  • HY-W838254
    1,2-Dipentadecanoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium

    		PKC Endogenous Metabolite Others
    1,2-Dipentadecanoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium functions as an activator for the protein kinase C family and is an anionic phospholipid found in mitochondrial and microsomal membranes, playing a crucial role in the composition of lung surfactant, particularly within the membranes of lamellar bodies in the lungs.
    1,2-Dipentadecanoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium
  • HY-117706
    LY 292728

    		Leukotriene Receptor Inflammation/Immunology
    LY 292728 is a potent leukotriene B4 (LTB4) receptor antagonist. LY 292728 binds to human neutrophils with a Ki of 0.47 nM and binds to guinea pig lung membranes with a Ki of 0.04 nM .
    LY 292728
  • HY-W839203
    22:0 PC

    1,2-Didocosanoyl-sn-glycero-3-phosphocholine; PC(22:0/22:0)

    		 Endogenous Metabolite Others
    22:0 PC (1,2-Didocosanoyl-sn-glycero-3-phosphocholine), a type of phosphatidylcholine, functions as a lung surfactant and is characterized as an amphipathic molecule predominantly found in the outer leaflets of biological membrane bilayers.
    22:0 PC
  • HY-149877
    hDHODH-IN-12

    		DNA/RNA Synthesis Dihydroorotate Dehydrogenase Cancer
    hDHODH-IN-12 is a potent DHODH inhibitor with an IC50 value of 0.421 μM. DHODH is the rate-limiting enzyme in the de novo synthesis of pyrimidine which is essential in DNA/RNA Synthesis. hDHODH-IN-12 is present in the inner membrane of human mitochondria.hDHODH-IN-12 can be used for the research of lung cancer .
    hDHODH-IN-12
  • HY-119682
    Bax agonist 1

    		Bcl-2 Family Apoptosis Cancer
    Bax agonist 1 (compound SMBA2) is a Bax agonist (Ki=57.2 nM). Bax agonist 1 induces Bax conformational changes by blocking S184 phosphorylation, promoting Bax insertion into the mitochondrial membrane and forming Bax oligomers, which induce cytochrome c release and apoptosis in malignant cancer cells expressing Bax. Bax agonist 1 can be used in lung cancer research .
    Bax agonist 1
  • HY-B0290S1
    Pranlukast-d4

    ONO-1078-d4

    		 Isotope-Labeled Compounds Leukotriene Receptor Endogenous Metabolite Inflammation/Immunology
    Pranlukast-d4 is deuterium labeled Pranlukast. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
    Pranlukast-d4
  • HY-P10226
    PGD97

    		Chloride Channel CFTR Endocrinology
    PGD97 is a selective cyclic peptide inhibitor against CAL/CFTR interactions, with a KD value of 6 nM towards the CAL PDZ domain for its desulfide cyclized form. PGD97 (desulfide cyclized form) has selectivity ≥ 130-fold compared to NHERF1/2 PDZ domains. PGD97 is capable of stabilizing F508del-CFTR at the cell membrane and improving CFTR function required for proper fluid homeostasis in tne lung. PGD97 can be used for the research of cystic fibrosis .
    PGD97

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: